Anakinra

Anakinra is a prescription medicine used to treat rheumatoid arthritis in adults and children 2 years of age and older. Anakinra is a type of medicine called an interleukin-1 (IL-1) receptor antagonist. It works by blocking the action of a chemical messenger in the body called interleukin-1 (IL-1) that contributes to inflammation and joint damage in rheumatoid arthritis. Anakinra helps to reduce swelling, tenderness, and pain in the joints.

Anakinra, sold under the brand name Kineret, is a biopharmaceutical medication used to treat several conditions:

1. Rheumatoid arthritis:

• Purpose: It is used as a second-line treatment to manage symptoms of rheumatoid arthritis (RA) in adults after treatment with disease-modifying antirheumatic drugs (DMARDs) has failed.
• Mechanism of action: Anakinra works by blocking the activity of interleukin-1 (IL-1), a protein involved in the inflammatory process. By blocking IL-1, Anakinra helps reduce inflammation, pain, and stiffness in the joints, improving symptoms and function in individuals with RA.

2. Cryopyrin-associated periodic syndromes (CAPS):

• Purpose: Anakinra is used to treat neonatal-onset multisystem inflammatory disease (NOMID), a rare and severe form of CAPS affecting infants. It can also be used to treat other forms of CAPS in adults and children.
• Mechanism of action: Similar to RA, Anakinra works by blocking IL-1, which plays a crucial role in the inflammatory process associated with CAPS. This helps control symptoms like fever, rash, joint pain, and inflammation in various organs.

3. Familial Mediterranean fever (FMF):

• Purpose: Anakinra can be used to treat acute attacks of FMF, a genetic disorder characterized by recurrent episodes of fever, abdominal pain, and inflammation in various body parts.
• Mechanism of action: As with other conditions, Anakinra helps control flares by blocking IL-1 and reducing inflammation.

4. Still's disease:

• Purpose: Anakinra is sometimes used as an off-label treatment for adult-onset Still's disease, a rare inflammatory disorder characterized by high fever, joint pain, rash, and other systemic symptoms. It is important to note that this is an off-label use, meaning it is not officially approved for this specific condition by regulatory bodies.

5. COVID-19:

• Purpose: Anakinra has received emergency use authorization (EUA) for the treatment of hospitalized adults with COVID-19 who require supplemental oxygen, a ventilator, or extracorporeal membrane oxygenation (ECMO).
• Mechanism of action: While the exact mechanism for COVID-19 is still under investigation, Anakinra is believed to help by reducing the excessive inflammatory response (cytokine storm) sometimes associated with severe COVID-19 cases.

Important considerations:

• Anakinra is administered by subcutaneous injection under the skin, typically daily.
• It can cause various side effects, including injection site reactions, headache, nausea, fatigue, and skin rash.
• It is crucial to consult with a healthcare professional to determine if Anakinra is the right treatment option for your specific condition and to understand the potential risks and benefits.